# Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)

> **NCT03184324** · PHASE2 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 211 (actual)

## Conditions studied

- Erosive Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** DWP14012
- **DRUG:** Esomeprazole
- **DRUG:** DWP14012 placebo
- **DRUG:** Esomeprazole placebo

## Key facts

- **NCT ID:** NCT03184324
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-28
- **Primary completion:** 2018-04-18
- **Final completion:** 2018-04-18
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2020-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03184324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03184324, "Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03184324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*